Market Overview

Antares Pharma Announces Availability of OTREXUP Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis in Children

Antares Pharma (NASDAQ: ATRS) today announced the availability of
OTREXUP™, the first U.S. Food and Drug Administration (FDA)
approved subcutaneous (SC) methotrexate (MTX) product for once weekly
self-administration with an easy-to-use, single dose, disposable auto
injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is
available at distribution centers throughout the USA.

See full press release

Posted-In: News Guidance Financing Management Global

 

Most Popular

Related Articles (ATRS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free